A detailed history of Daiwa Securities Group Inc. transactions in Immunovant, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 537 shares of IMVT stock, worth $14,772. This represents 0.0% of its overall portfolio holdings.

Number of Shares
537
Previous 537 -0.0%
Holding current value
$14,772
Previous $14,000 7.14%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

SELL
$30.27 - $43.79 $1,664 - $2,408
-55 Reduced 9.29%
537 $17,000
Q4 2023

Jan 31, 2024

BUY
$31.31 - $44.19 $2,254 - $3,181
72 Added 13.85%
592 $25,000
Q4 2022

Feb 06, 2023

BUY
$6.59 - $17.75 $830 - $2,236
126 Added 31.98%
520 $9,000
Q3 2021

Nov 05, 2021

BUY
$7.01 - $11.37 $1,472 - $2,387
210 Added 114.13%
394 $3,000
Q4 2020

Feb 04, 2021

BUY
$36.36 - $52.71 $6,690 - $9,698
184 New
184 $8,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.